Objective:To investigate the prognostic value of radiomics features based on ^(18)F-FDG PET/CT imaging for advanced non-small cell lung cancer(NSCLC)treated with chemotherapy.Methods:A sample of 146 NSCLC patients sta...Objective:To investigate the prognostic value of radiomics features based on ^(18)F-FDG PET/CT imaging for advanced non-small cell lung cancer(NSCLC)treated with chemotherapy.Methods:A sample of 146 NSCLC patients stagedⅢor stageⅣwere included in this retrospective study who received ^(18)F-FDG PET/CT before treatment.All patients were treated with standardized chemotherapy after PET/CT examination and were divided into training group and validation group in an 8:2 ratio randomly.Radiomics features were extracted.In the training group,the minimum absolute contraction and selection operator(LASSO)algorithm and Cox risk proportional regression model were used to screen radiomics and clinical prognostic factors of progression-free survival(PFS).The radiomic model,clinical model and complex model were established respectively.The corresponding scores were calculated,then verified in the validation group.Results:The LASSO algorithm finally screened four radiomics features.ROC results showed that in the training group,the AUC of PFS predicted by the radiomics model was 0.746,and that in the verification group was 0.622.COX multivariate analysis finally included three clinical features related to PFS in NSCLC patients,namely pathological type,clinical stage and MTV30.The AUC for predicting PFS by clinical model,radiomics model and composite model were 0.746,0.753 and 0.716,respectively.The radiomics model had the highest diagnostic efficacy,and its sensitivity and specificity were 0.663 and 0.833,respectively.Delong test verified that there was no statistical difference in the predictive efficacy between the radiomics model and the composite model(Z=1.777,P=0.076)and the clinical imaging model(Z=0.323,P=0.747).Conclusion:The radiomics model based on PET/CT has a good predictive value for the prognosis of advanced NSCLC treated with chemotherapy,but it needs further validation before it can be widely used in clinical practice.展开更多
Objective:To explore the relationship between multimodal imaging features and metabolic parameters derived from^(18)F-FDG PET/CT and the mutation status of epidermal growth factor receptor(EGFR)and the expression of p...Objective:To explore the relationship between multimodal imaging features and metabolic parameters derived from^(18)F-FDG PET/CT and the mutation status of epidermal growth factor receptor(EGFR)and the expression of programmed cell death ligand 1(PD-L1)in non-small cell lung cancer(NSCLC),so as to provide objective evidence for clinical screening of targeted therapy and immunotherapy beneficiaries.Methods:Data of NSCLC patients who underwent^(18)F-FDG PET/CT scans,EGFR mutation and PD-L1 expression tests with confirmed pathological results were collected.The differences of PET/CT morphological characteristics and metabolic parameters between the EGFR mutation and the wild group,and between the PD-L1 expression positive and the negative group were analyzed.Univariate and multivariate logistic regression analyses were used to test the correlation between clinical and PET/CT parameters and EGFR mutation and PD-L1 expression status.Results:MTV(P=0.01)and TLG(P=0.00)values of EGFR mutant patients were statistically lower than those of wild type patients.Univariate and multivariate logistic analysis showed that age(P=0.03),smoking history(P=0.00)and MTV(P=0.00)were independent risk factors for EGFR mutation.The positive expression of PD-L1 in stageⅢ/Ⅳgroup was significantly higher than that in stageⅠ/ⅡGroup(P=0.01),but there was no significant difference in different age,gender,smoking history,SUVmax,MTV,TLG,LDH and CEA groups.Logistic univariate analysis showed that only stage was associated with the positive expression rate of PD-L1(P=0.01).There was no significant correlation between PET/CT parameters and PD-L1 status.Conclusion:PET/CT metabolic parameters MTV,age and smoking history are independent predictors of EGFR mutation,which is expected to provide objective evidence for clinical screening of targeted treatment beneficiaries;however,PET/CT metabolic parameters are not good in predicting PD-L1 protein expression,which needs to be further verified by large sample.展开更多
The present study explored the 18-kDa translocator protein radioligand ^(18)F-PBR06 as a PET imaging biomarker for diagnosis of inflammation and compared it with ^(18)F-FDG for differentiation of inflammation and lung...The present study explored the 18-kDa translocator protein radioligand ^(18)F-PBR06 as a PET imaging biomarker for diagnosis of inflammation and compared it with ^(18)F-FDG for differentiation of inflammation and lung tumors in animals.^(18)F-PBR06 was synthesized with an average decay-corrected radiochemical yield of 30–40%(end of synthesis, EOS), and the radiochemical purity was greater than 99%. The inflammation-to-blood ratio of ^(18)FPBR06(3.53 ± 0.26) was higher than the tumor-to-blood ratio(1.77 ± 0.35)(P \ 0.001). The inflammation-tomuscle ratio of ^(18)F-PBR06(2.33 ± 0.64) was also higher than the tumor-to-muscle ratio(1.45 ± 0.14)(P = 0.036).Micro-PET/CT images showed high uptake of ^(18)F-FDG in both inflamed muscles and lung tumor tissues. However,^(18)F-PBR06 uptake in inflamed muscles remained higher than that in the lung tumor tissues, following 90 min of dynamic Micro-PET/CT imaging. Further, macrophages in the inflammatory regions showed a higher fluorescence signal than in lung tumor tissues. Results of the study confirmed that ^(18)F-PBR06 PET/CT imaging allowed for diagnosis of inflammation. Moreover,^(18)F-PBR06 uptake in the inflammatory regions was significantly higher than in lung tumor tissues, suggesting that ^(18)F-PBR06 PET/CT imaging has potential to differentiate between peripheral lung cancer and inflammation nodules.展开更多
Objective: We investigated the correlation between the number of circulating tumor cells(CTCs) and wholebody metabolic tumor volume(WBMTV) measured by 18 F-fluorodeoxyglucose(FDG) positron emission tomography/computed...Objective: We investigated the correlation between the number of circulating tumor cells(CTCs) and wholebody metabolic tumor volume(WBMTV) measured by 18 F-fluorodeoxyglucose(FDG) positron emission tomography/computed tomography(PET/CT).The aim was to evaluate the value of the incorporation of CTC number and WBMTV in the prognostic prediction of stage III small-cell lung cancer(SCLC).Methods: One hundred and twenty-nine patients were enrolled in this study.All patients were treated with four cycles of a platinum-based regimen and concurrent chest irradiation,followed by prophylactic cranial irradiation.Blood samples for CTC analysis were obtained from 112 patients before the initiation of chemotherapy(as a baseline),after cycle 1 and after cycle 4.CTCs were measured using the CELLSEARCH? system.The patients underwent pretreatment FDG PET/CT WBMTV,which included all malignant lesions.The Spearman rank test was used to determine the correlation among CTC counts,WBMTV and disease stage.Overall survival(OS) and progression-free survival(PFS) curves were produced using the Kaplan-Meier method,and survival differences between groups were assessed by the log-rank test.Results: The number of CTCs at baseline did not correlate with WBMTV before the initiation of therapy(P=0.241).The number of CTCs at baseline and the WBMTV before the initiation of therapy were independent relevant factors for PFS and OS.The subgroup analysis(Group A: CTC count >19.5 and a WBMTV >266.5cm~3;Group B: CTC count >19.5 and a WBMTV ≤266.5cm~3; Group C: CTC count ≤19.5 and a WBMTV >266.5cm~3;Group D: CTC count ≤19.5 and a WBMTV ≤266.5cm~3) showed that the differences were statistically significant in the median PFS(Group A vs.D,P<0.001; Group B vs.D,P=0.018; Group C vs.D,P=0.029) and in the median OS(Group A vs.D,P<0.001; Group B vs.D,P=0.012).Conclusions: CTC number and WBMTV are related to progression and death in patients with SCLC.The incorporation of CTC number and WBMTV scans can provide a detailed prognostic prediction for SCLC.展开更多
Lung cancer presents a high prevalence around the world and constitutes the leading cause of death due to cancer in men and women. Proper staging is essential in order to provide the correct treatment and estimate sur...Lung cancer presents a high prevalence around the world and constitutes the leading cause of death due to cancer in men and women. Proper staging is essential in order to provide the correct treatment and estimate survival. PET/CT imaging is the method of choice for the staging of lung cancer patients with a better performance than the traditional imaging methods. It allows defining the primary tumor more clearly, separating it from the atelectasis and neighboring fibrotic changes, thus achieving an improved T evaluation while optimizing the target definition for radiotherapy. It presents greater sensibility and specificity than Computed Tomography (CT) when assessing the extra-thoracic and thoracic lymph nodes, modifying the N stage with regard to the traditional study in up to 25% of patients. PET/CT imaging is the method with the best performance for detecting extra-encephalic metastasis and for detecting unexpected lesions in up to 30% of patients. In order to achieve proper encephalic staging, a Magnetic Resonance Imaging scan must be performed or, a CT scan of the brain concomitant to the PET/CT. One to eight percent of lung cancer patients who are subjected to PET/CT imaging present a synchronous secondary extra pulmonary or pulmonary cancer when being diagnosed, with significant prognostic and therapeutic implications. PET/CT imaging has proven to be a valuable tool for survival prognosis with regard to the initial uptake of the tumor and the early response (interim) or final response to chemotherapy, although it is not routinely used for evaluating therapy. The PET/MRI is an emerging hybrid technique with certain advantages, such as less exposure to radiation in comparison to PET/CT and greater contrast resolution of the MRI images. However, its usefulness has not been validated yet for lung cancer patients.展开更多
目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术...目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术前1周内进行了18F-F DG P ET/CT显像检查,并在术后3~6个月内进行了复查,监测复发或转移情况。术前的TNM分期和术后的复发转移情况均以手术病理结果或临床随访结果为金标准进行评估。结果术前分期诊断中,18F-FD(G P ET/CT显像的T分期、N分期和M分期的符合率分别为86.59%、81.93%和100%,一致性检验Kappa值分别为0.834、0.793和1.000。术后的复发转移检测中,18F-FDG PET/CT显像在术后6个月内成功检出了22例(88.00%)的复发转移病例,其诊断灵敏度为88.00%,特异度为100.00%。结论18F-FDG PET/CT显像在肺癌术前分期以及术后复发转移的预测中具有较高的准确性和可靠性,该方法可以为临床提供有效的参考信息,有助于医生制定更准确的治疗方案和更有效的随访策略。展开更多
Objective： To investigate the validity of CT perfusion in assessing angiogenic activity of lung cancer. Methods： Fifty-six patients with lung cancer scheduled for elective surgical resection received 16-slice helica...Objective： To investigate the validity of CT perfusion in assessing angiogenic activity of lung cancer. Methods： Fifty-six patients with lung cancer scheduled for elective surgical resection received 16-slice helical CT perfusion imaging. Time-density curve （TDC）, blood flow （BF）, blood volume （BV）, mean transmit time （MTT） and permeability surface area product （PS） were calculated. 18F-deoxyglucose-positron emission tomography （FGD-PET） was carried out in 14 out of the 56 patients to calculate standardized uptake values （SUVs）. Tumor microvessel density （MVD） was examined using CD34 immunohistochemical staining of the resected tumor tissue. Pearson’s correlation analysis was used to evaluate potential correlation between CT perfusion parameters and MVD or SUV. Results： Average time to peak height （TPH） of the TDCs （including two types of TDC） was 24.38±5.69 seconds. Average BF, BV, MTT and PS were 93.42±53.45 ml/100g/min,93.42±53.45 ml/100g,6.83±4.51 s and 31.92±18.73 ml/100g/min, respectively. Average MVD was 62.04±29.06/HPF. The mean SUV was 6.33±3.26. BF was positively correlated with MVD （r=0.620,P0.01） and SUV （r=0.891, P0.01）. PS was also positively correlated with SUV （r=0.720, P0.05）. A positive correlation was also observed between tumor MVD and SUV （r=0.915, P0.01）. Conclusions： CT perfusion imaging is a reliable tool to evaluate the tumor neovascularity of lung cancer.展开更多
Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field of non-small cell lung cancer (N...Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field of non-small cell lung cancer (NSCLC). <sup>18</sup>F-FDG PET/CT, as a noninvasive and effective examination technique, reflects the location and functional information of tumor lesions through the metabolic level of glucose. Studies have shown that PD-L1 may affect the sugar metabolism of tumor cells. Therefore, <sup>18</sup>F-FDG PET/CT can be used to predict the expression of PD-L1 and evaluate the efficacy of immunotherapy. This article mainly introduces the relationship between PD-L1 expression and NSCLC, the advantages of <sup>18</sup>F-FDG PET/CT, the imaging mechanism of <sup>18</sup>F-FDG PET/CT based on PD-L1 and its research progress in NSCLC, and the role of <sup>18</sup>F-FDG PET/CT in the response and efficacy evaluation of immunotherapy in NSCLC, aiming to provide a reference for the clinic.展开更多
基金Research and Cultivation Foundation of Hainan Medical College(HYPY2020022)Hainan Natural Science Foundation Youth fund(822QN482)+1 种基金Doctoral Research Fund project of Hainan Cancer Hospital(2022BS04)Key R&D projects in Hainan Province(ZDYF2021SHFZ244)。
文摘Objective:To investigate the prognostic value of radiomics features based on ^(18)F-FDG PET/CT imaging for advanced non-small cell lung cancer(NSCLC)treated with chemotherapy.Methods:A sample of 146 NSCLC patients stagedⅢor stageⅣwere included in this retrospective study who received ^(18)F-FDG PET/CT before treatment.All patients were treated with standardized chemotherapy after PET/CT examination and were divided into training group and validation group in an 8:2 ratio randomly.Radiomics features were extracted.In the training group,the minimum absolute contraction and selection operator(LASSO)algorithm and Cox risk proportional regression model were used to screen radiomics and clinical prognostic factors of progression-free survival(PFS).The radiomic model,clinical model and complex model were established respectively.The corresponding scores were calculated,then verified in the validation group.Results:The LASSO algorithm finally screened four radiomics features.ROC results showed that in the training group,the AUC of PFS predicted by the radiomics model was 0.746,and that in the verification group was 0.622.COX multivariate analysis finally included three clinical features related to PFS in NSCLC patients,namely pathological type,clinical stage and MTV30.The AUC for predicting PFS by clinical model,radiomics model and composite model were 0.746,0.753 and 0.716,respectively.The radiomics model had the highest diagnostic efficacy,and its sensitivity and specificity were 0.663 and 0.833,respectively.Delong test verified that there was no statistical difference in the predictive efficacy between the radiomics model and the composite model(Z=1.777,P=0.076)and the clinical imaging model(Z=0.323,P=0.747).Conclusion:The radiomics model based on PET/CT has a good predictive value for the prognosis of advanced NSCLC treated with chemotherapy,but it needs further validation before it can be widely used in clinical practice.
基金This study was supported by Research and Cultivation Foundation of Hainan Medical College(No.HYPY2020022)Hainan Natural Science Foundation Youth fund(No.822QN482)Doctoral Research Fund Project of Hainan Cancer Hospital(No.2022BS04)。
文摘Objective:To explore the relationship between multimodal imaging features and metabolic parameters derived from^(18)F-FDG PET/CT and the mutation status of epidermal growth factor receptor(EGFR)and the expression of programmed cell death ligand 1(PD-L1)in non-small cell lung cancer(NSCLC),so as to provide objective evidence for clinical screening of targeted therapy and immunotherapy beneficiaries.Methods:Data of NSCLC patients who underwent^(18)F-FDG PET/CT scans,EGFR mutation and PD-L1 expression tests with confirmed pathological results were collected.The differences of PET/CT morphological characteristics and metabolic parameters between the EGFR mutation and the wild group,and between the PD-L1 expression positive and the negative group were analyzed.Univariate and multivariate logistic regression analyses were used to test the correlation between clinical and PET/CT parameters and EGFR mutation and PD-L1 expression status.Results:MTV(P=0.01)and TLG(P=0.00)values of EGFR mutant patients were statistically lower than those of wild type patients.Univariate and multivariate logistic analysis showed that age(P=0.03),smoking history(P=0.00)and MTV(P=0.00)were independent risk factors for EGFR mutation.The positive expression of PD-L1 in stageⅢ/Ⅳgroup was significantly higher than that in stageⅠ/ⅡGroup(P=0.01),but there was no significant difference in different age,gender,smoking history,SUVmax,MTV,TLG,LDH and CEA groups.Logistic univariate analysis showed that only stage was associated with the positive expression rate of PD-L1(P=0.01).There was no significant correlation between PET/CT parameters and PD-L1 status.Conclusion:PET/CT metabolic parameters MTV,age and smoking history are independent predictors of EGFR mutation,which is expected to provide objective evidence for clinical screening of targeted treatment beneficiaries;however,PET/CT metabolic parameters are not good in predicting PD-L1 protein expression,which needs to be further verified by large sample.
基金funded in part by the National Natural Science Foundation of China(Nos.11875114,81471706,and 81871407)Science and Technology Commission of Shanghai Municipality(No.16410722700)sponsored by the Shanghai Sailing Program(No.17YF1417400)
文摘The present study explored the 18-kDa translocator protein radioligand ^(18)F-PBR06 as a PET imaging biomarker for diagnosis of inflammation and compared it with ^(18)F-FDG for differentiation of inflammation and lung tumors in animals.^(18)F-PBR06 was synthesized with an average decay-corrected radiochemical yield of 30–40%(end of synthesis, EOS), and the radiochemical purity was greater than 99%. The inflammation-to-blood ratio of ^(18)FPBR06(3.53 ± 0.26) was higher than the tumor-to-blood ratio(1.77 ± 0.35)(P \ 0.001). The inflammation-tomuscle ratio of ^(18)F-PBR06(2.33 ± 0.64) was also higher than the tumor-to-muscle ratio(1.45 ± 0.14)(P = 0.036).Micro-PET/CT images showed high uptake of ^(18)F-FDG in both inflamed muscles and lung tumor tissues. However,^(18)F-PBR06 uptake in inflamed muscles remained higher than that in the lung tumor tissues, following 90 min of dynamic Micro-PET/CT imaging. Further, macrophages in the inflammatory regions showed a higher fluorescence signal than in lung tumor tissues. Results of the study confirmed that ^(18)F-PBR06 PET/CT imaging allowed for diagnosis of inflammation. Moreover,^(18)F-PBR06 uptake in the inflammatory regions was significantly higher than in lung tumor tissues, suggesting that ^(18)F-PBR06 PET/CT imaging has potential to differentiate between peripheral lung cancer and inflammation nodules.
基金supported by a grant from the National Health and Family Planning Commission of China(No.201402011)
文摘Objective: We investigated the correlation between the number of circulating tumor cells(CTCs) and wholebody metabolic tumor volume(WBMTV) measured by 18 F-fluorodeoxyglucose(FDG) positron emission tomography/computed tomography(PET/CT).The aim was to evaluate the value of the incorporation of CTC number and WBMTV in the prognostic prediction of stage III small-cell lung cancer(SCLC).Methods: One hundred and twenty-nine patients were enrolled in this study.All patients were treated with four cycles of a platinum-based regimen and concurrent chest irradiation,followed by prophylactic cranial irradiation.Blood samples for CTC analysis were obtained from 112 patients before the initiation of chemotherapy(as a baseline),after cycle 1 and after cycle 4.CTCs were measured using the CELLSEARCH? system.The patients underwent pretreatment FDG PET/CT WBMTV,which included all malignant lesions.The Spearman rank test was used to determine the correlation among CTC counts,WBMTV and disease stage.Overall survival(OS) and progression-free survival(PFS) curves were produced using the Kaplan-Meier method,and survival differences between groups were assessed by the log-rank test.Results: The number of CTCs at baseline did not correlate with WBMTV before the initiation of therapy(P=0.241).The number of CTCs at baseline and the WBMTV before the initiation of therapy were independent relevant factors for PFS and OS.The subgroup analysis(Group A: CTC count >19.5 and a WBMTV >266.5cm~3;Group B: CTC count >19.5 and a WBMTV ≤266.5cm~3; Group C: CTC count ≤19.5 and a WBMTV >266.5cm~3;Group D: CTC count ≤19.5 and a WBMTV ≤266.5cm~3) showed that the differences were statistically significant in the median PFS(Group A vs.D,P<0.001; Group B vs.D,P=0.018; Group C vs.D,P=0.029) and in the median OS(Group A vs.D,P<0.001; Group B vs.D,P=0.012).Conclusions: CTC number and WBMTV are related to progression and death in patients with SCLC.The incorporation of CTC number and WBMTV scans can provide a detailed prognostic prediction for SCLC.
文摘Lung cancer presents a high prevalence around the world and constitutes the leading cause of death due to cancer in men and women. Proper staging is essential in order to provide the correct treatment and estimate survival. PET/CT imaging is the method of choice for the staging of lung cancer patients with a better performance than the traditional imaging methods. It allows defining the primary tumor more clearly, separating it from the atelectasis and neighboring fibrotic changes, thus achieving an improved T evaluation while optimizing the target definition for radiotherapy. It presents greater sensibility and specificity than Computed Tomography (CT) when assessing the extra-thoracic and thoracic lymph nodes, modifying the N stage with regard to the traditional study in up to 25% of patients. PET/CT imaging is the method with the best performance for detecting extra-encephalic metastasis and for detecting unexpected lesions in up to 30% of patients. In order to achieve proper encephalic staging, a Magnetic Resonance Imaging scan must be performed or, a CT scan of the brain concomitant to the PET/CT. One to eight percent of lung cancer patients who are subjected to PET/CT imaging present a synchronous secondary extra pulmonary or pulmonary cancer when being diagnosed, with significant prognostic and therapeutic implications. PET/CT imaging has proven to be a valuable tool for survival prognosis with regard to the initial uptake of the tumor and the early response (interim) or final response to chemotherapy, although it is not routinely used for evaluating therapy. The PET/MRI is an emerging hybrid technique with certain advantages, such as less exposure to radiation in comparison to PET/CT and greater contrast resolution of the MRI images. However, its usefulness has not been validated yet for lung cancer patients.
文摘目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术前1周内进行了18F-F DG P ET/CT显像检查,并在术后3~6个月内进行了复查,监测复发或转移情况。术前的TNM分期和术后的复发转移情况均以手术病理结果或临床随访结果为金标准进行评估。结果术前分期诊断中,18F-FD(G P ET/CT显像的T分期、N分期和M分期的符合率分别为86.59%、81.93%和100%,一致性检验Kappa值分别为0.834、0.793和1.000。术后的复发转移检测中,18F-FDG PET/CT显像在术后6个月内成功检出了22例(88.00%)的复发转移病例,其诊断灵敏度为88.00%,特异度为100.00%。结论18F-FDG PET/CT显像在肺癌术前分期以及术后复发转移的预测中具有较高的准确性和可靠性,该方法可以为临床提供有效的参考信息,有助于医生制定更准确的治疗方案和更有效的随访策略。
基金supported by grants from The National Key Technology R&D Program of China(No. 2009BAI86B00)Research in the Special Needs of Critical Care Technology and Equipment(No. 2009BAI86B05)PLA General Hospital Nursery Fund (No. 09KMM38)
文摘Objective： To investigate the validity of CT perfusion in assessing angiogenic activity of lung cancer. Methods： Fifty-six patients with lung cancer scheduled for elective surgical resection received 16-slice helical CT perfusion imaging. Time-density curve （TDC）, blood flow （BF）, blood volume （BV）, mean transmit time （MTT） and permeability surface area product （PS） were calculated. 18F-deoxyglucose-positron emission tomography （FGD-PET） was carried out in 14 out of the 56 patients to calculate standardized uptake values （SUVs）. Tumor microvessel density （MVD） was examined using CD34 immunohistochemical staining of the resected tumor tissue. Pearson’s correlation analysis was used to evaluate potential correlation between CT perfusion parameters and MVD or SUV. Results： Average time to peak height （TPH） of the TDCs （including two types of TDC） was 24.38±5.69 seconds. Average BF, BV, MTT and PS were 93.42±53.45 ml/100g/min,93.42±53.45 ml/100g,6.83±4.51 s and 31.92±18.73 ml/100g/min, respectively. Average MVD was 62.04±29.06/HPF. The mean SUV was 6.33±3.26. BF was positively correlated with MVD （r=0.620,P0.01） and SUV （r=0.891, P0.01）. PS was also positively correlated with SUV （r=0.720, P0.05）. A positive correlation was also observed between tumor MVD and SUV （r=0.915, P0.01）. Conclusions： CT perfusion imaging is a reliable tool to evaluate the tumor neovascularity of lung cancer.
文摘Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field of non-small cell lung cancer (NSCLC). <sup>18</sup>F-FDG PET/CT, as a noninvasive and effective examination technique, reflects the location and functional information of tumor lesions through the metabolic level of glucose. Studies have shown that PD-L1 may affect the sugar metabolism of tumor cells. Therefore, <sup>18</sup>F-FDG PET/CT can be used to predict the expression of PD-L1 and evaluate the efficacy of immunotherapy. This article mainly introduces the relationship between PD-L1 expression and NSCLC, the advantages of <sup>18</sup>F-FDG PET/CT, the imaging mechanism of <sup>18</sup>F-FDG PET/CT based on PD-L1 and its research progress in NSCLC, and the role of <sup>18</sup>F-FDG PET/CT in the response and efficacy evaluation of immunotherapy in NSCLC, aiming to provide a reference for the clinic.
